Provozní marže společnosti Knight Therapeutics
Jaká je hodnota metriky Provozní marže společnosti Knight Therapeutics?
Hodnota metriky Provozní marže společnosti Knight Therapeutics, Inc. je 2.37%
Jaká je definice metriky Provozní marže?
Provozní marže (Operation margin) je procentuální poměr provozních příjmů z čistých tržeb.
Operating margin is an indicator of profitability and is often used to compare the profitability of companies and industries of differing sizes. Companies are collections of projects and markets, individual areas can be judged on how successful they are at adding to the corporate net profit. Not all projects are of equal size, however, and one way to adjust for size is to divide the profit by sales revenue. The resulting ratio is the percentage of sales revenue that gets 'returned' to the company as net profits after all the related costs of the activity are deducted.
Provozní marže společností v sektoru Health Care sektor na TSX ve srovnání se společností Knight Therapeutics
Čemu se věnuje společnost Knight Therapeutics?
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer. The company also provides Burinex, for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome; PROBUPHINE, to treat opioid addiction; and MOVANTIK for the treatment of opioid-induced constipation. In addition, it offers Vidaza to treat myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven to treat advanced or metastatic breast cancer; Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma; Ladevina to treat multiple myeloma; Zyvalix for metastatic prostate cancer; Karfib to treat relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; AmBisome and Cresemba to treat fungal infection; and Impavido for leishmaniasis. Further, the company provides Ursofalk to treat biliary cirrhosis; Salofalk for ulcerative colitis; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Firmy s metrikou provozní marže podobnou společnosti Knight Therapeutics
- Hodnota metriky Provozní marže společnosti Bilfinger SE je 2.36%
- Hodnota metriky Provozní marže společnosti Vicon je 2.36%
- Hodnota metriky Provozní marže společnosti Anacle Systems je 2.36%
- Hodnota metriky Provozní marže společnosti K&S je 2.36%
- Hodnota metriky Provozní marže společnosti NSK je 2.37%
- Hodnota metriky Provozní marže společnosti China Yongda Automobiles Services je 2.37%
- Hodnota metriky Provozní marže společnosti Knight Therapeutics je 2.37%
- Hodnota metriky Provozní marže společnosti Eolus Vind AB (publ) je 2.37%
- Hodnota metriky Provozní marže společnosti Ricoh je 2.37%
- Hodnota metriky Provozní marže společnosti Megaport je 2.37%
- Hodnota metriky Provozní marže společnosti CHS je 2.37%
- Hodnota metriky Provozní marže společnosti CHS je 2.37%
- Hodnota metriky Provozní marže společnosti Muehlhan AG je 2.37%